Articles

Find an Article

Filter articles

Applied Filters

Showing 211 to 220 of 273 results

New recipes for Tomatoes and Broccoli

EU03-03-2015

Controversial patents covering a fruit and a vegetable are awaiting their fate at the Enlarged Board of Appeal. LSIPR examines the likelihood of their succeeding.

After Alice: the two-step rule

US30-01-2015Judith Kim and Scott Schaller

Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe.

PlasmaTech: two strings to its bow

US26-11-2014

At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP.

Pursuing agribusiness infringement actions in Brazil

Brazil04-11-2014Gabriel Di Blasi

Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi.

Patenting Parthenotes

EU04-11-2014Franz-Josef Zimmer and Markus Grammel

Earlier this year, the Advocate General of 
the CJEU opined that stem cells from parthenotes are patentable. Franz-Josef Zimmer and Markus Grammel examine the reasoning behind his opinion.

A changing landscape: approving biosimilar products in Mexico

Mexico03-11-2014José Trigueros

Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.

Ebola IP rights 
in focus

US03-11-2014

The current outbreak of Ebola has devastated communities in West Africa. It has also thrown a light on the complex web of IP rights surrounding the possible treatments for this serious and usually fatal virus, as LSIPR discovered.

HGS: where are we now with SPCs?

EU29-10-2014Ashley Roughton

Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS.

Challenges to the patenting of “essentially biological processes” in India

India29-10-2014Swarup Kumar and Shivaarti Bajaj

A recent decision from the IPAB on the patent eligibility of biological processes could change the biotech playing field in India, say Swarup Kumar and Shivaarti Bajaj.

An alliance for science

US30-09-2014

The Bay Area of California has one 
of the greatest concentrations of life 
sciences companies in the world, 
but its biotech community is being 
threatened by the seemingly 
unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler, 
vice chair, of the new North Bay 
Life Science Alliance to find out 
how it plans to strengthen the network in the area.

Showing 211 to 220 of 273 results

LSIPR